INTRODUCTION {#S1}
============

Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is increasingly used for hematological malignancies([@R1]). Allo-HSCT can be far more demanding than other cancer treatments for patients and families([@R2]). Recipients require a fulltime caregiver 24/7 for the first 100 days post-transplant or longer. Post-transplant, caregivers must monitor the recipient for numerous complications such as graft versus host disease while providing social and practical support, e.g., transportation([@R3]). Programs often require that patients remain near the treating hospital thus requiring relocation so emergent issues can be managed by staff trained in Allo-HSCT. Multiple challenges take place while caregivers must additionally balance personal responsibilities (job and other family members). Thus allo-HSCT caregivers experience uncontrollable stressors associated with increased depression and anxiety including a decline of their loved-one\'s health, separation from their social support and uncertainty about patient prognoses([@R3], [@R4]).

Depression and anxiety are strikingly elevated in both cancer patients and their caregivers([@R5]) as well as Allo-HSCT caregviers([@R3]). Allo-HSCT caregivers request help in meeting their patient needs, navigating care transitions, and finding social and emotional support([@R6]). The Surgeon General provided a prescription for caregivers of reducing stress, attending to depression and anxiety, identifying sources of support, maintaining physical health, and receiving education regarding patient illness([@R7]). In addition to psychological toll of caregiving, there may be hidden biologic costs to caring for cancer patients([@R8]) similar to those reported in other caregiver populations([@R9], [@R10]). Although decrements in cancer caregiver well-being have been reported([@R11]), physiological consequences in Allo-HSCT caregivers have not been reported.

Psychosocial interventions targeting distress of cancer caregivers are needed([@R12]), yet there are relatively few([@R13]) and trials of these intervention suffer from methodological problems([@R14]). The present randomized clinical trial (RCT) tested a psychosocial intervention for Allo-HSCT caregiver\'s unique needs that addressed the Surgeon General\'s recommendations([@R7]). We modified an efficacious cognitive-behavioral stress management intervention for cancer *patients* to meet the unique needs of Allo-HSCT *caregivers* based on clinical experience, stakeholder input, and a transactional stress and coping model([@R15], [@R16]). We added a supplementary means for the participants to create a brief relaxing respite though the use of a biofeedback device approved for blood pressure reduction that paces and slows respiration ([@R17]) which we felt would facilitate relaxation. As the primary *[behavioral]{.ul}* outcome, stress was assessed via the Perceived Stress Scale (PSS)([@R18]) due to the scale measuring a sense of control. As the primary *[physiological]{.ul}* outcome, the cortisol awakening response (CAR) represents the change, typically a rise, in salivary cortisol between awakening and 30 min later and is tied to anticipation of the upcoming day\'s activities, high demands the preceding day, or depression([@R19], [@R20]). CAR is reduced in depression([@R20], [@R21]) as well as in caregivers([@R22]) and is negatively associated with the PSS([@R23]). We hypothesized that the intervention would mitigate distress in caregivers such that at the three-month intervention completion point, caregivers randomized to stress management would have 1) reduced PSS, 2) increased CAR, 3) a decline in secondary psychological outcomes (e.g., anxiety and depression) and 4) reduced markers of immune disturbance in comparison to those randomized to TAU.

METHODS {#S2}
=======

Eligibility Criteria {#S3}
--------------------

Caregivers and their patients were recruited consecutively between 11/2008 and 4/2012 during pre-transplant screening of *[all]{.ul}* Allo-HSCT patients (n= 267) and their caregivers at a single site (Presbyterian St. Luke\'s Medical Center, Denver, CO). Caregiver inclusion criteria included caring for an Allo-HSCT patient at least 50% of the time during the first 100 days post-transplant, able to speak/read English, 18 years or older, and with telephone access; their patients must have received an Allo-HSCT, able to speak/read English, and 18 years or older. Exclusion criteria included history of psychiatric illness (based on caregiver report) in the past 18 months (*[unrelated]{.ul}* to patient illness) or diagnosis of medical condition or medications that might affect biomarkers. Caregivers and patients provided informed consent approved by the Colorado Multiple Institutional Review Board. Collecting demographics or information from those refusing consent was not permitted. Thirty-two non-caregiving controls were recruited from the university community to provide a comparison group for the biomarkers which did not have widely accepted norms (See [Supplemental Information](#SD3){ref-type="supplementary-material"} for description).

Study Design {#S4}
------------

Consented participants (n=148 caregivers) were randomized with intent-to-treat by permuted block design to either PsychoEducation, Paced Respiration and Relaxation (PEPRR) or treatment as usual (TAU) as indicated in the CONSORT diagram([@R24]) in [Figure 1](#F1){ref-type="fig"}(also see additional comments in Footnote). The biostatistician (SKM-G) developed the randomization allocation which was available only to the site coordinator (TLS).

Intervention {#S5}
------------

PEPRR consisted of eight semi-structured 1-on-1 sessions with a master\'s level social worker beginning 16 ± 10 days (Mean ± SD) post-transplant (transplantation day set as 0). Sessions were based on an intervention for cancer *[patients]{.ul}* ([@R16]) which we modified to address Allo-HSCT *[caregiver]{.ul}* specific needs. PEPRR utilized a Transactional Model of Stress and Coping, which predicts that those able to handle and adapt to the challenges of caregiving using tools taught in the program will show lower levels of stress([@R16]). This approach has been the basis for numerous effective interventions and shown to improve coping and adaptation to stressful life events([@R25]).

Sessions began on average 2 weeks post-transplant and continued weekly to complete all sessions before the three month assessment. Sessions lasted 60-75 min, were manualized, and followed the same order with some flexibility in content as needed. To minimize caregiver burden, all sessions took place at the hospital when caregivers were visiting with their patients during hospitalization or at the clinic during times when caregivers brought patients to appointments.

Sessions included in order: 1) program overview, instructions for biofeedback device (see below), and introduction to stress management, 2) impact of stress on physical and emotional health, 3) how thoughts and emotions lead to stress, 4) coping skills training, 5) management of fatigue, sleep, and other health behaviors, 6) addressing lack of control, uncertainty, and fear, 7) improving partner communication strategies and adapting to changing role(s), and 8) effective utilization of social support. A workbook including session topics was provided for use during sessions with homework recommended but not assessed. Interventionist fidelity (\>90%) to the manual was randomly checked by video for 20% of sessions. Details of this intervention are the subject of a subsequent report.

Caregivers randomized to PEPRR also received a biofeedback device, RESPeRATE® (InterCure, Fort Luc, NJ), with established efficacy for reducing hypertension([@R17]). The RESPeRATE® entrained respiration to specific tones which increased in duration to slow and deepen respiration. Caregivers were asked to use this device for 15 min at least 4-5 times/week to facilitate relaxation. The device recorded participant\'s use and this data was uploaded to address adherence. Of the research participants randomized to PEPRR, only 12 caregivers (16%) showed consistent (weekly) use for the device throughout the intervention phase with overall usage by others declining by the third week after beginning PEPRR. Adherence and satisfaction with this device was mixed and will be reported elsewhere.

All caregivers were encouraged to avail themselves of programs at the transplant clinic including individual counseling, support groups and education classes. These voluntary programs focused on caregiving stress, taking care of oneself, identifying important community resources, and specific problems raised by participants. Support in navigating the complex HSCT program (e.g., arranging local housing following patient hospital discharge, insurance, diet restrictions, etc.) was also available. Programs were free of charge to anyone who wanted assistance (family and/or caregivers) and were attended at least one time by 16.1% of the TAU group and 7.2% of the PEPRR group during the 100 day post-transplant period. TAU caregivers received follow up calls from research staff to sustain study retention, set up return appointments, and encourage questionnaire completion.

Psychological Outcomes {#S6}
----------------------

Questionnaires were completed prior to study randomization and patient transplant (M=-1 day relative to transplant which was treated as day zero, SD=10) reflecting Baseline, and at Month 1 (M=37 days post-transplant, SD=10) and Month 3 (M=93 days post-transplant, SD=14). The Month 1 assessment was typically completed after 1-2 intervention sessions and the Month 3 assessment always occurred after completion of the full program. Instruments were anchored to the preceding month and included the primary psychological outcome, the 14 item Perceived Stress Scale (PSS)([@R18]), a validated self-report of control over stress which we have shown to be elevated in Allo-HSCT caregivers([@R3]) and other caregivers([@R26]). Secondary psychological outcomes included depression (Center for Epidemiological Studies Depression scale, CESD score)([@R27]) and state anxiety (State-Trait Anxiety Inventory, STAI score)([@R28]) which show significant elevation in cancer patients and caregivers([@R5])([@R5]). The Caregiver Reaction Assessment (CRA)([@R29]) assessed post-transplant changes in burden. Total mood disturbance (Profile of Mood States, POMS-TMD)([@R30]), sleep (Pittsburgh Sleep Quality Inventory, PSQI)([@R31]), mental and physical health (Short Form Health Survey Version 2, SF-36 summary scales)([@R32]), and trauma (Impact of Events Scale, IES)([@R33]) were evaluated. All instruments have excellent validity and reliability. Of caregivers enrolled at baseline and those remaining at 1 and 3 month collection times, 99, 93, and 90% returned their questionnaires respectively. Since the focus was on caregivers and to minimize burden, patients completed *[only]{.ul}* demographic questionnaires and SF-36 at times corresponding to caregivers.

A caregiver composite distress score (CG-Distress) was created by principal component analysis (PCA) on 5 affective variables (PSS, POMS-TMD, CESD, STAI, and IES) at each time and a composite measure of caregiver physical "well-being" (CG-Well-being) summed standardized scores of CG-Distress, PSQI, CRA, and SF-36 Physical score as described elsewhere([@R3]).

Physiological Outcomes {#S7}
----------------------

The cortisol awakening response (CAR)([@R19]) was the primary physiological outcome. A comprehensive panel of physiological markers ([Supplemental Information](#SD3){ref-type="supplementary-material"}) reflecting neuroendocrine status (diurnal salivary cortisol and DHEA) and immune parameters (natural cytotoxicity and inflammation) were collected as secondary physiological outcomes from caregivers at the time of questionnaire completion.

Statistical analysis {#S8}
--------------------

To allow sufficient (≥ 90%) statistical power based on existing literature ([@R36])([@R34]) to detect small to medium effect sizes (ES), 170 pairs of caregivers and their corresponding patients were initially targeted. Funding cut-backs lowered this to 148 caregivers with their corresponding patients, which still provided power to detect ESs greater than 0.27, after allowing for planned attrition. Intent-to-treat analyses (including all randomized participants after removing one screen failure) used SPSS version 20.0 (IBM Corporation) and SAS version 9.3 (SAS Institute, Inc.) software. Baseline differences between PEPRR and TAU caregivers and patients on demographic and other key variables were assessed by chi-square and independent t-tests or nonparametric Mann-Whitney U and Fisher\'s Exact tests when data distributions were non-normal. Patient' and caregiver age was compared by paired t-test between TAU and PEPRR. Analyses of Variance (ANOVAs) compared biomarker levels at baseline among PEPRR and TAU caregivers and non-caregiving controls. Patterns of missing data were evaluated with chi-square tests comparing PEPRR and TAU groups at each time.

Caregiver outcomes were analyzed by mixed models analyses of covariance (ANCOVA) using Satterthwaite approximation for degrees of freedom providing group estimates at each month with fixed effects of intervention (PEPRR, TAU), month (Baseline, Month1 and Month 3), and their interaction while co-varying for caregiver age because older age is associated with greater resilience in response to challenge([@R35]). Repeated measures were assumed to have unstructured covariance([@R36]). To provide some protection for multiple comparisons([@R37]), group effects were tested at month 3 *only if* the omnibus test of the global null hypothesis (i.e. means for each group by month combination were equal) was rejected. Effect Sizes (ESs) at month 3 were calculated as (MTAU - MPEPRR)/SD, where MTAU and MPEPRR represents adjusted means of TAU and PEPRR respectively at month 3 for outcomes and standard deviation (SD) was computed as the square root of estimated variance of each outcome at Month 3. Comparisons utilized a two-tailed, 0.05 significance level. Outcomes collected at 6 and 12 months are not included here but are an ongoing secondary analysis.

RESULTS {#S9}
=======

Sample Characteristics {#S10}
----------------------

Neither caregiver nor patient characteristics differed by randomization group. Tests evaluating continuous outcomes indicated variances were similar between groups. Caregivers averaged 53.5 years (range 21-80) and were predominately female (75.7%)/Caucasian (89.9%) consistent with caregiver demographics([@R38]). During this recruiting period, the percentage of all males presenting for Allo-HSCT at this clinic was 65.3% and thus the consented sample was representative of this clinic\'s patients. Fully employed caregivers declined from 48% pre-transplant to 23.7% post-transplant. Complete details are provided in [Table 1](#T1){ref-type="table"}.

Half of patients (54.1%) were diagnosed with leukemia. Patients' illness demographics were similar across groups ([Table 1](#T1){ref-type="table"}) with one exception; time to neutrophil engraftment \[absolute neutrophil count \>500/microliter for three consecutive days([@R39])\] was 2.5 days earlier for TAU compared to PEPRR (p=.04). Since engraftment and first intervention session occurred around the same day (+16 days), this was unlikely related to group assignment. During the 100 days post-transplant, a total of 11 patients died representing 6 in TAU and 5 in PEPRR. Although encouraged to continue completing questionnaires and the intervention, only two caregivers from PEPRR returned questionnaires while none completed the intervention. However all available caregiver data is included in the intent to treat design.

Prior to randomization, perceived stress (PSS) exceeded population norms of 19.2 for this age range([@R40]). Scores on the CESD for individual caregivers approached and occasionally exceeded published depression cutoffs of 16 ([@R27])([Table 2](#T2){ref-type="table"}). Scores greater than 16 triggered a clinical follow up by staff regardless of group assignment ([Table 2](#T2){ref-type="table"}). Elevated anxiety and poor sleep based on national norms were also noted in caregivers prior to intervention. There was no difference between groups at baseline in psychological measures based on randomization as indicated in [Table 2](#T2){ref-type="table"}.

Efficacy Outcomes {#S11}
-----------------

Chi-square tests confirmed no differences between groups in the pattern of missing data. Of 148 participants, 18.9% and 17.9% were missing data respectively on primary psychological and physiological outcomes across months. Caregivers typically found the intervention acceptable with 70% completing all eight sessions. Reasons for drop-out included inadequate time (n=10), patient becoming gravely ill (n=2), or patient death (n=11) and did not differ by group. [Table 3](#T3){ref-type="table"} presents model estimates (Mean, 95% CI) by month for PEPRR and TAU for primary and secondary psychological outcomes based on ANCOVAs of outcomes by group, month, and interaction. Caregiver age was a significant covariate (p\'s\<.05); younger caregivers reported greater distress as predicted([@R35]). All main effects and interaction test results are reported in [Table 3](#T3){ref-type="table"} regardless of significance as well as post hoc comparisons and estimated ESs for the three month comparisons *only when interactions were significant*.

A *reliable pattern of reduced distress* at month three across psychological measures was noted for participants receiving PEPRR ([Table 3](#T3){ref-type="table"}). [Figure 2](#F2){ref-type="fig"} shows model predictions for the primary outcome, PSS. At three months post-transplant, PEPRR caregivers were significantly lower than TAU for PSS \[t~(117)~=2.09; p=0.039\] with an ES of 0.39 which declined below population norms at three months whereas PSS in TAU *increased*. Similarly anxiety and depression were significantly lower in PEPRR compared to TAU with ESs of 0.66 and 0.46, respectively. This overall pattern held for total mood disturbance (POMS-TMD) as well as the composite distress score. Graphic model predictions with confidence intervals for anxiety ([Figure 3](#F3){ref-type="fig"}) and depression ([Figure 4](#F4){ref-type="fig"}) are provided. Consistency across multiple psychological domains supports that PEPRR is efficacious in mitigating distress in spite of increasing caregiver burden (CRA) reflecting rising demand post-transplant.

Unlike reports of other caregiver populations([@R9], [@R10]), caregivers' biomarkers at baseline did not differ from non-caregiving controls ([Supplemental Information Table A](#SD1){ref-type="supplementary-material"}). CAR and other caregivers' biomarkers did not change as a function of intervention nor with regard to time ([Supplemental Table B](#SD2){ref-type="supplementary-material"}). Consequently, detailed descriptions of methods, analysis, and results of primary and secondary physiological outcomes are provided as [Supplementary Information](#SD3){ref-type="supplementary-material"}.

DISCUSSION {#S12}
==========

Allo-HSCT caregivers are highly distressed during the transplant process. The present observations are significant because they indicate that distress commonly reported in caregivers([@R3], [@R41]) can be mitigated by a semi-structured psychosocial intervention tailored to meet the needs of Allo-HSCT caregivers. Comparable reductions in distress have also been reported for Alzheimer\'s patient caregivers receiving a similar intervention([@R42]).

Visual inspection suggests a trend for a decline in caregiver distress in both groups one month post-transplant ([Table 3](#T3){ref-type="table"}) during patient hospitalization. At discharge 2-5 weeks post-transplant, Allo-HSCT caregivers assume full burden of care. Increasing caregiver burden (see CRA, [Table 3](#T3){ref-type="table"}) post-transplant indicated the realities of an Allo-HSCT, e.g., uncertainties, sudden changes in patient\'s physical condition, and most of all increased caregiver demands following discharge. Despite rising caregiver burden, the ability to attenuate key psychological markers through eight sessions of stress management training is significant in this challenging situation.

Reduced distress in caregivers are consistent with patient populations receiving a similar intervention. For example, breast cancer patients receiving this intervention showed reduced depression([@R25]). Although HIV+ males receiving a similar intervention revealed changes in plasma cortisol and DHEA([@R43]), the present study noted no changes. This difference may be due to the physiological disruption present in HIV+ participants unlike the present caregivers (see [Supplemental Information](#SD3){ref-type="supplementary-material"}) in spite of significant psychological distress. Caregiver\'s self-reported physical health score also remained close to population norms ([@R32]) throughout the first 100 days (see [Table 3](#T3){ref-type="table"}) suggesting participants were relatively healthy.

A lack of physiological disruption as measured by the CAR and other secondary biomarkers differs from reports of physiological disturbance in caregivers of other patient populations([@R8]-[@R10]). This was unanticipated in light of signficant psychological distress. Reasons for this discrepancy may include duration of Allo-HSCT caregiving, patient prognosis, and/or a bias to select only healthy caregivers for Allo-HSCT patients. Interestingly, duration of caregiving is rarely reported in caregiver research but when reported it often exceeds four years([@R4]). For the present group, the average time since cancer diagnosis, and importantly not necessarily caregiving per se, was 26 months, full caregiving responsibilities may not begin until the patient is discharged from the hospital following transplant. It is likely the impact of the cancer diagnosis and/or caregiving stress on physiological functioning is not measurable in during the current timeframe. Longitudinal studies of these caregivers are needed to address this question more fully and are presently underway.

Secondly, Allo-HSCT is a relatively efficacious treatment option([@R1]) with up to 70% long term survival compared to the experiences of caring for progressive decline in cognitively impaired persons([@R44]). Thus shorter caregiving duration and better prognosis for Allo-HSCT patients may have contributed to the lack of differences in biomarkers in Allo-HSCT caregivers compared to other caregiver groups. Longer term caregiving represents a chronic stressor affecting allostatic load wherein regulation of the hypothalamic pituitary adrenal (HPA) axis and other stress responsive systems are disrupted([@R45]).

Poor sleep is associated with increased inflammation ([@R46]). However self-reported caregiver sleep([@R31]) and inflammatory markers were not affected by PEPRR which was also unrelated to the caregiver\'s symptom experience in the immediate post-transplant period. That is, the composite physical well-being score from the SF36 was stable and within population norms([@R32]). We have observed a similar pattern of good physical health in caregivers of Phase 1 trial cancers patients in the presence of considerable psychological distress([@R41]). Medically healthy caregivers are necessary given the rigor of the Allo-HSCT procedure. Caregivers undergo significant prescreening before approval raising a potential selection bias against disrupted physiological regulation.

The median 100 day cost for Allo-HSCT is \$203,206 (USD) covering all aspects of the treatment([@R47]). Caregiver intervention delivered by a social worker represented about 12-14 care hours. Mean pay for a master\'s level social worker is approximately \$24.28/hr (May, 2011, United States Bureau of Labor Statistics), representing less than \$350. The biofeedback devices cost less than \$150 bringing the cost of this intervention to \$500. An allogeneic transplant is impossible without a caregiver 24/7. This comes at a cost to the caregiver in terms of mental health consequences as well as lost wages. Similar coping training for Alzheimer\'s caregivers was cost neutral and associated with improved caregiver quality of life([@R48]).The burden of caregiving for a loved one with cancer clearly points to a need for a cost-benefit analysis of providing cancer caregiver intervention(s) as part of the standard of care for families experiencing an Allo-HSCT. A future cost effectiveness analysis of the present approach is definitely warranted.

Several limitations were present. First the demographics of this particular clinic limited the diversity of caregivers creating a relatively homogenous group as well as a relatively small sample size. Second, there was a single interventionist. Third, we did not address differences in the caregiver-patient dyadic relationships. Fourth, we did not assess patient quality of life based on commonly accepted approaches. Finally, caregiver\'s personal health and well-being may affect the quality of support caregivers provide their patients in significant and poorly understood ways which we did not assess. These limitations are targets of a multisite trial currently underway utilizing this intervention.

In summary in spite of increasing caregiver burden post-transplant, PEPRR proved to be efficacious in mitigating the corresponding psychological 4distress in Allo-HSCT caregivers. Recuing distress has the potential benefit of improving caregiver well-being and thus may permit the caregiver to be more effective in fulfilling their caregiver task(s).
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Regarding consistency of the information reported to [ClinicalTrials.gov](http://ClinicalTrials.gov), a contract agency for the Protocol Coordinator for NCI\'s PDQ® Cancer Clinical Trials Registry, Office of Communications and Education National Cancer Institute initially entered the trial information at [ClinicalTrials.Gov](http://ClinicalTrials.Gov) using our approved IRB submission. We assumed this was the process for this new (2008) federal reporting requirement and believed we had performed our due diligence. We received a confirmation that the trial was recorded on February 23, 2009 although we had received a registration number prior to that date. We began recruitment only after that number was filed and we received approval by our IRB. When the responsibility of maintaining this information was shifted from NCI to the study site three years later we realized that many errors were made by the contracting agency in the description of our protocol and we did our best to correct the errors. The first author takes full responsibility for errors in reporting at [ClinicalTrials.gov](http://ClinicalTrials.gov). However from a CONSORT perspective, a clear analysis plan was in place prior to breaking the blind. Although inadvertently omitted from the reported plan, we had planned two analysis stages: 1) an ITT analysis of the 3 month intervention once all subjects had completed that assessment and the blind was broken and 2) a second analysis that would commence once all subjects their final one-year evaluation time point.

![CONSORT diagram ([@R24]) representing subject flow and attrition through the study. From 267 patient-caregiver pairs approached, 149 were consented and 148 were randomized. Reasons for dropout are indicated as well as numbers available for analysis. See Footnote.](nihms-674186-f0001){#F1}

![Primary psychological outcome of Perceived Stress Score (PSS) ([@R18]). Model predictions at Baseline and months 1 and 3 post-transplant for treatment as usual (TAU) \[open symbols, broken line\] and the intervention, Psychoeducation, Paced Respiration, and Relaxation (PEPRR), \[filled symbols, solid line\] with 95% CI at each collection time are shown. The horizontal broken line indicates the population mean in a healthy comparably aged population ([@R40]).](nihms-674186-f0002){#F2}

![Secondary psychological outcome of anxiety based on the Spielberger State Anxiety Score ([@R28]). Model predictions at Baseline and months 1 and 3 post-transplant for treatment as usual (TAU) \[open symbols, broken line\] and the intervention, Psychoeducation, Paced Respiration, and Relaxation (PEPRR), \[filled symbols, solid line\] with 95% CI at each collection time are shown for this secondary psychological outcome. The horizontal broken line indicates the population mean in a healthy comparably aged population ([@R28]).](nihms-674186-f0003){#F3}

![Secondary psychological outcome of depression based on the CESD ([@R27]). Model predictions at Baseline and months 1 and 3 post-transplant for treatment as usual (TAU) \[open symbols, broken line\] and the intervention, Psychoeducation, Paced Respiration, and Relaxation (PEPRR), \[filled symbols, solid line\] with 95% CI at each collection time are shown for this secondary psychological outcome. The horizontal broken line indicates the clinical cut off score for depression risk ([@R27]).](nihms-674186-f0004){#F4}

###### 

Baseline Characteristics of Caregivers and Patients

  Characteristics                                             OVERALL (n = 148)                                 TAU (n = 74)        PEPRR (n = 74)      Significance^[d](#TFN4){ref-type="table-fn"}^
  ----------------------------------------------------------- ------------------------------------------------- ------------------- ------------------- -----------------------------------------------
                                                              **Caregivers^[b](#TFN2){ref-type="table-fn"}^**                                           
  Age, mean (CI), y                                           53.5 (51.5, 55.5)                                 54.8 (51.9, 57.7)   52.2 (49.4, 55.1)   p=0.21
  Sex, n (%)                                                                                                                                            
      Female                                                  112 (75.7)                                        56 (75.7)           56 (75.7)           
      Male                                                    35 (23.6)                                         17 (23.0)           18 (24.3)           p=0.88
  Ethnicity, n (%)                                                                                                                                      
      Caucasian                                               133 (89.9)                                        68 (91.9)           65 (87.8)           
      Other                                                   12 (8.2)                                          4 (5.5)             8 (10.9)            p=0.24
  Education, n (%)                                                                                                                                      
      College or above                                        117 (79.1)                                        57 (77.0)           60 (81.1)           p=0.52
  Annual income \$, n (%)                                                                                                                               
      \< 25,000                                               24 (16.2)                                         13 (17.6)           11 (14.9)           
      25,000-44,999                                           29 (19.6)                                         15 (20.3)           14 (18.9)           
      45,000-64,999                                           26 (17.6)                                         11 (14.9)           15 (20.3)           
      \> 65,000                                               60 (40.5)                                         31 (41.9)           29 (39.2)           p=0.83
  Relationship, n (%)                                                                                                                                   
      Spouse/partner                                          103 (69.6)                                        46 (62.2)           57 (77.0)           
      Parent                                                  27 (18.2)                                         19 (25.7)           8 (10.8)            
      Other                                                   16 (10.8)                                         8 (10.8)            8 (10.8)            p=0.06
  Employment Status, n (%)                                                                                                                              
      Before Caregiving                                                                                                                                 
          Full-time                                           71 (48.0)                                         35 (47.3)           36 (48.6)           
          Part-time                                           24 (16.2)                                         11 (14.9)           13 (17.6)           
          Unemployed                                          15 (10.1)                                         8 (10.8)            7 (9.5)             
          On leave                                            3 (2.0)                                           1 (1.4)             2 (2.7)             
          Retired                                             29 (19.6)                                         16 (21.6)           13 (17.6)           p=0.93
      During Caregiving                                                                                                                                 
          Full-time                                           35 (23.6)                                         16 (21.6)           19 (25.7)           
          Part-time                                           17 (11.5)                                         7 (9.5)             10 (13.5)           
          Unemployed                                          22 (14.9)                                         14 (18.9)           8 (10.8)            
          On leave                                            36 (24.3)                                         17 (23.0)           19 (25.7)           
          Retired                                             30 (20.3)                                         15 (20.3)           15 (20.3)           p=0.64
                                                                                                                                                        
                                                              **Patients^[c](#TFN3){ref-type="table-fn"}^**                                             
  Age, mean (CI), y                                           49.5 (47.4, 51.6)                                 48.0 (44.8, 51.2)   51.1 (48.2, 53.9)   p=0.15
  Sex, n (%)                                                                                                                                            
      Female                                                  47 (31.8)                                         27 (36.5)           20 (27.0)           
      Male                                                    97 (65.5)                                         46 (62.2)           51 (68.9)           p=0.26
  Ethnicity, n (%)                                                                                                                                      
      Caucasian                                               116 (78.4)                                        59 (79.7)           57 (77.0)           
      Other                                                   9 (6.1)                                           3 (4.1)             6 (8.1)             p=0.49^[e](#TFN5){ref-type="table-fn"}^
  Education, n (%)                                                                                                                                      
      College or above                                        93 (62.8)                                         49 (66.2)           44 (59.5)           p=0.33
  Annual income \$, n (%)                                                                                                                               
      \< 25,000                                               31 (20.9)                                         17 (23.0)           14 (18.9)           
      25,000-44,999                                           25 (16.9)                                         12 (16.2)           13 (17.6)           
      45,000-64,999                                           22 (14.9)                                         13 (17.6)           9 (12.2)            
      \> 65,000                                               46 (31.1)                                         20 (27.0)           26 (35.1)           p=0.61
  Patient Diagnosis^[a](#TFN1){ref-type="table-fn"}^, n (%)                                                                                             
      Leukemia                                                80 (54.1)                                         40 (54.1)           40 (54.1)           
      Lymphoma                                                25 (16.9)                                         14 (18.9)           11 (14.9)           
      MDS/MPS                                                 26 (17.6)                                         12 (16.2)           14 (18.9)           
      Other (MM, SAA)                                         15 (10.1)                                         7 (9.5)             8 (10.8)            p=0.90
  Duration of Illness, mean (CI), m                           25.9 (20.1, 31.8)                                 28.8 (19.5, 38.1)   23.2 (15.8, 30.5)   p=0.80^[f](#TFN6){ref-type="table-fn"}^
  Transplant conditioning intensity, n (%)                                                                                                              
      Myeloablative                                           71 (39.4)                                         36 (48.6)           35 (47.3)           
      Non-myeloablative                                       24 (13.3)                                         10 (13.5)           14 (18.9)           
      Reduce intensity                                        47 (26.1)                                         26 (35.1)           21 (28.4)           p=0.55
  Time To Engraftment, mean (CI), d                           16.0 (14.9, 17.1)                                 14.8 (13.3, 16.4)   17.3 (15.7, 18.8)   p=0.04^[f](#TFN6){ref-type="table-fn"}^

Abbrevations: MDS, myelodysplastic syndrome; MPS, myeloproliferative syndrome; MM, multiple myeloma; SAA, severe aplastic anemia.

Caregiver information was not available for TAU for the following variables: age (n = 1), sex (n = 1), ethnicity (n = 2), education (n = 2), annual income (n = 4), relationship (n = 1) employment status before caregivng (n = 3) and after caregivng (n = 5). PEPRR for the following variables: ethnicity (n = 1), education (n = 2), annual income (n = 5), relationship (n = 1) employment status before caregiving (n = 3) and after caregivng (n = 3).

Patient information was not available for TAU for the following variables: age (n = 1), sex (n = 1), ethnicity (n = 12), education (n = 9), annual income (n = 12), patient diagnosis (n = 1), duration of illness (n = 3), transplant conditioning intensity (n = 2) and time to engraftment (n = 17). PEPRR for the following variables: age (n = 2), sex (n = 3), ethnicity (n = 11), education (n = 9), annual income (n = 12), patient diagnosis (n = 1), duration of illness (n = 1), transplant conditioning intensity (n = 4) and time to engraftment (n = 19).

Significance based on independent t-test or Pearson\'s Chi-square test as appropriate.

Significance based on Fisher\'s Exact Test.

Significance based on Mann Whitney U Test.

###### 

Baseline Assessment Means and 95% CIs for Caregivers

                                              Mean (95% CI)^[b](#TFN8){ref-type="table-fn"}^                                                 
  ------------------------------------------- ------------------------------------------------ ---------------------- ---------------------- --------
  **PRIMARY OUTCOME**                                                                                                                        
                                                                                                                                             
          **PSS**                             23.11 (21.71, 24.51)                             23.11 (21.00, 25.23)   23.10(21.21, 24.99)    p=0.99
                                                                                                                                             
  **SECONDARY OUTCOMES**                                                                                                                     
                                                                                                                                             
          **CESD**                            15.22 (13.62, 16.82)                             15.52 (13.19, 17.85)   14.93(12.69, 17.18)    p=0.72
          **STAI-STATE**                      40.60 (38.84, 42.37)                             42.08 (39.40, 44.77)   39.16(36.85, 41.48)    p=0.10
          **POMS-TMD**                        63.53 (57.62, 69.44)                             64.90 (56.30, 73.50)   61.65 (53.30, 70.00)   p=0.59
          **CRA**                             10.27 (9.91, 10.62)                              10.31 (9.77, 10.84)    10.23 (9.75, 10.71)    p=0.84
          **PSQI**                            11.28 (10.81, 11.76)                             11.10 (10.44, 11.76)   11.47 (10.77, 12.16)   p=0.45
          **SF-36: Mental Summary Score**     43.94 (41.98, 45.89)                             42.98 (39.97, 45.99)   44.90 (42.35, 47.44)   p=0.33
          **SF-36: Physical Summary Score**   54.34 (52.97, 55.70)                             53.67 (51.66, 55.68)   55.00(53.11, 56.89)    p=0.34
          **IES**                             30.65 (29.28, 32.03)                             31.39 (29.49, 33.28)   29.94 (27.93, 31.96)   p=0.30
                                                                                                                                             
  **COMPOSITE SCORES**                                                                                                                       
                                                                                                                                             
          **CG-Distress**                     0.00 (−.17, .17)                                 0.06 (−.20, .31)       −0.05 (−.28, .18)      p=0.52
          **CG-Wellbeing**                    0.01 (−.48, .50)                                 0.09 (−.61, .78)       −0.06 (−.76, .65)      p=0.77

Abbreviations: PSS, Perceived Stress Scale; CESD, Center for Epidemiologic Studies Depression; STAI-State, State-Trait Anxiety Inventory-State; POMS-TMD, Profile of Mood States-Total Mood Disturbance; CRA, Caregiver Reaction Assessment; PSQI, Pittsburgh Sleep Quality Index; SF-36, Short Form Health Survey; IES, Impact of Events Scale; CG-Distress, Caregiver Distress Composite Score; CG-Wellbeing, Caregiver Wellbeing Composite Score.

Information was not available for TAU for the following variables: PSS (n = 4), CESD (n = 5), STAI-STATE (n = 3), POMS-TMD (n = 4), CRA (n = 5), PSQI (n = 3), SF-36: Mental Summary Score (n = 4), SF-36: Physical Summary Score (n = 4), IES (n = 4), CG-Distress (n = 8), CG-Wellbeing (n = 10), Information was not available for PEPRR for the following variables: PSS (n = 2), CESD (n = 2), STAI-STATE (n = 1), POMS-TMD (n = 1), CRA (n = 1), PSQI (n = 1), SF-36: Mental Summary Score (n = 4), SF-36: Physical Summary Score (n = 4), IES (n = 2), CG-Distress (n = 4), CG-Wellbeing (n = 6).

Significance based on independent t-test

###### 

Estimates and Test Results from Mixed Model Analyses of Covariance for Primary and Secondary Psychological Outcomes and Composite Scores

  Outeome^[a](#TFN10){ref-type="table-fn"}^   Interventation Group   Mean (95% CI) Baseline   Mean (95% CI) Month 1   Mean (95% CI) Month 3   Model Tests: Main Effects         Model Tests: Interaction                     Month 3 Group^[b](#TFN11){ref-type="table-fn"}^ Comparison Effect Size
  ------------------------------------------- ---------------------- ------------------------ ----------------------- ----------------------- --------------------------------- -------------------------------------------- ------------------------------------------------------------------------
  **PRIMARY OUTCOME**                                                                                                                                                                                                        
                                                                                                                                                                                                                             
  **PSS**                                     **PEPRR**              22.7 (20.9, 24.6)        22.0 (20.1, 23.8)       20.0 (17.9, 22.0)       Group: F~1,141~= 0.92; p =0.34    **Group\*Month: F~2,112~= 4.08; p =0.020**   t~117~=2.09; p=0.039
                                              **TAU**                23.5 (21.6, 25.3)        21.6 (19.7, 23.5)       23.0 (21.0, 25.0)       Month: F~2,112~= 3.43; p =0.036   ES= 0.39                                     
                                                                                                                                                                                                                             
  **SECONDARY OUTCOMES**                                                                                                                                                                                                     
                                                                                                                                                                                                                             
  **CESD**                                    **PEPRR**              14.6 (12.5, 16.8)        13.6 (11.6, 15.5)       12.1 (9.8, 14.5)        Group: F~1,142~= 2.11; p =0.15    **Group\*Month: F~2,116~= 3.66; p =0.029**   t~117~=2.46; p=0.016
                                              **TAU**                15.9 (13.7, 18.1)        13.8 (11.8, 15.8)       16.3 (14.0, 18.6)       Month: F~2,116~= 2.54; p =0.083   ES=0.46                                      
  **STAI-State**                              **PEPRR**              38.9 (36.6, 41.3)        38.0 (35.7, 40.4)       34.7 (31.9, 37.5)       Group: F~1,137~= 6.33; p =0.013   **Group\*Month: F~2,115~= 6.10; p =0.003**   t~109~=3.42; p=0.0009
                                              **TAU**                42.4 (40.0, 44.8)        38.8 (36.4, 41.2)       41.6 (38.8, 44.4)       Month: F~2,115~= 4.60; p =0.012   ES=0.66                                      
  **POMS-TMD**                                **PEPRR**              61.0 (53.2, 68.9)        59.4 (51.8, 67.0)       53.0 (44.8, 61.2)       Group: F~1,142~= 1.31; p =0.25    **Group\*Month: F~2,116~= 4.62; p =0.012**   t~114~=2.09; p=0.039
                                              **TAU**                66.8 (58.9, 74.8)        58.0 (50.2, 65.7)       65.2 (57.1, 73.3)       Month: F~2,116~= 2.95; p =0.56    ES =0.39                                     
  **CRA**                                     **PEPRR**              10.2 (9.7, 10.6)         10.8 (10.3, 11.4)       10.6 (9.9, 11.2)        Group: F~1,145~=0.27; p =0.60     Group\*Month: F~2,110~= 0.92; p =0.40        \-
                                              **TAU**                10.4 (9.9, 10.8)         10.8 (10.2, 11.4)       10.9 (10.3, 11.5)       Month: F~2,110~=8.19; p=0.0005                                                 
  **PSQI**                                    **PEPRR**              11.4 (10.8, 12.1)        11.2 (10.6, 11.9)       11.0 (10.3, 11.7)       Group: F~1,137~=0.01; p =0.92     Group\*Month: F~2,110~= 0.83; p =0.44        \-
                                              **TAU**                11.1 (10.4, 11.7)        11.2 (10.6, 11.9)       11.2 (10.5, 11.9)       Month: F~2,110~=0.25; p =0.78                                                  
  **SF36-Mental**                             **PEPRR**              45.1 (42.6, 47.7)        45.7 (42.9, 48.4)       47.0 (43.9, 50.0)       Group: F~1,138~=2.62; p =0.11     Group\*Month: F~2,116~= 0.29; p =0.75        \-
                                              **TAU**                42.7 (40.1, 45.3)        43.8 (41.0, 46.6)       43.5 (40.6, 46.4)       Month: F~2116~=0.72; p =0.49                                                   
  **SF36-Physical**                           **PEPRR**              54.7 (52.8, 56.6)        52.9 (50.6, 55.2)       54.0 (51.8, 56.1)       Group: F~1,136~=0.00; p =0.98     Group\*Month: F~2,109~= 181; p =0.17         \-
                                              **TAU**                53.8 (51.9, 55.7)        54.0 (51.7, 56.3)       53.7 (51.6, 55.8)       Month: F~2,109~=1.04; p =0.36                                                  
  **IES**                                     **PEPRR**              29.8 (27.9, 31.7)        29.1 (27.1, 31.1)       28.4 (26.1, 30.8)       Group: F~1,138~=2.01; p =0.16     Group\*Month: F~2,116~= 0.03; p =0.97        \-
                                              **TAU**                31.4 (29.5, 33.3)        31.0 (29.0, 33.0)       30.3 (28.0, 32.6)       Month: F~2,116~=1.19; p =0.31                                                  
                                                                                                                                                                                                                             
  **COMPOSITE SCORES**                                                                                                                                                                                                       
                                                                                                                                                                                                                             
  **CG-Distress**                             **PEPRR**              −0.11 (−0.33, 0.11)      −0.09 (−0.32, 0.15)     −0.22 (−0.48, 0.05)     Group: F~1,139~=2.55; p =0.11     **Group\*Month: F~2,109~= 4.02; p =0.021**   t~114~=2.39; p=0.019
                                              **TAU**                0.12 (−0.11, 0.34)       −0.03 (−0.28, 0.21)     0.23 (−0.03, 0.49)      Month: F~2,109~=0.77; p =0.46     ES=0.45                                      
  **CG-Wellbeing**                            **PEPRR**              −0.13 (−0.79, 0.52)      −0.20 (−0.86, 0.45)     −0.31 (−1.03, 0.39)     Group: F~1,132~=0.74; p =0.39     Group\*Month: F~2,102~= 2.69; p =0.073       
                                              **TAU**                0.18 (−0.48, 0.85)       −0.17 (−0.83, 0.49)     0.45 (−0.25, 1.16)      Month: F~2,102~=1.80; p =0.17                                                  

Abbreviations: PSS, Perceived Stress Scale; CESD, Center for Epidemiologic Studies Depression; STAI-State, State-Trait Anxiety Inventory-State; POMS-TMD, Profile of Mood States-Total Mood Disturbance; CRA, Caregiver Reaction Assessment; PSQI, Pittsburgh Sleep Quality Index; SF-36, Short Form Health Survey; IES, Impact of Events Scale; CG-Distress, Caregiver Distress Composite Score; CG-Wellbeing, Caregiver Wellbeing Composite Score.

Month 3 group post hoc t-test comparison and corresponding estimated effect size (ES) when Group\*Month interaction was significant.
